Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Alastair Gray a Health Economics Research Centre, Department of
Public Health, University of Oxford, Institute of Health Sciences,
Oxford OX3 7LF, b Department of Primary Health Care, University of Oxford,
Institute of Health Sciences, c Diabetes Trials Unit, Nuffield
Department of Clinical Medicine, University of Oxford, Oxford OX2
6HE
Correspondence
to: A Gray
Objective:
To estimate the incremental cost of
implementing policies for intensive control of blood glucose
concentration and blood pressure for all patients with type 2 diabetes
in England.
What is already known on this topic
Current levels of diabetes care in England need to be improved, but the
total cost and the implications for NHS staffing are unknown What this study adds
About 720 additional staff would be required to implement these control
policies, especially specialist nurses and practice nurses The advent of primary care trusts and the national service framework
for diabetes should create new incentives and mechanisms to adopt these
improved standards
alastair.gray{at}ihs.ox.ac.uk
Design:
Extrapolation of resource use and cost data derived from a randomised controlled trial.
Setting:
General practice, outpatient care, and
inpatient care.
Population:
Trial population with diagnosed type 2 diabetes in England extrapolated to the population of England.
Main outcome measures:
Total costs based on use of
healthcare resources including costs of management, treatment, and hospitalisation.
Results:
The incremental net annual cost of
implementing intensive control of blood glucose and blood pressure to
all people with diagnosed type 2 diabetes in England is estimated to be
£100.5m ($156m;
159m), which is equivalent to less than 1% of the
proposed additional annual expenditure on the NHS in 2001-5. This
estimate varied in sensitivity analyses from £67m to £121m.
Conclusions:
Policies to improve control of blood
glucose and blood pressure of people with type 2 diabetes are effective in reducing complications associated with the disease and are also cost
effective. The total cost represents a small fraction of the NHS's
spending plans.
The United Kingdom Prospective Diabetes Study (UKPDS) has shown that
policies of intensive control of blood glucose concentration and blood
pressure for people with type 2 diabetes are cost effective
interventions
Implementing the main findings of the UKPDS to all people with
diagnosed type 2 diabetes in England would have a net annual cost of
around £100m, which equates to 1% of the planned increase in annual
expenditure on the NHS over the period 2001-5
Read all Rapid Responses